摘要
目的:探讨华蟾素胶囊联合FOLFOX方案治疗结直肠癌(colorectal cancer,CRC)患者的效果。方法:选取2022年1月—2023年2月肇庆市第一人民医院收治的70例CRC患者临床资料进行研究,根据是否采用华蟾素分为观察组(35例)和对照组(35例)。对照给予FOLFOX方案治疗,观察组在对照组基础上给予华蟾素胶囊治疗。比较两组近期疗效,治疗前后血清肿瘤标志物、炎症因子、Karnofsky功能状态(KPS)评分,治疗期间各项毒副反应发生情况。结果:观察组近期总有效率高于对照组,差异有统计学意义(P<0.05)。治疗前,两组糖类抗原242(carbohydrate antigen 242,CA242)、糖类抗原(carbohydrate antigen 125,CA125)、癌胚抗原(carcinoembryonic antigen,CEA)、白细胞介素1β(interleukin-1β,IL-1β)、白细胞介素-6(interleukin-6,IL-6)、肿瘤坏死因子-α(tumor necrosis factor-α,TNF-α)、KPS评分比较,差异无统计学意义(P>0.05);治疗后,两组CA242、CA125、CEA、IL-1β、IL-6、TNF-α水平较治疗前降低,且观察组低于对照组,差异有统计学意义(P<0.05);治疗后,两组KPS评分较治疗前提高,且观察组高于对照组,差异有统计学意义(P<0.05)。观察组治疗期间胃肠道反应、白细胞减少发生率低于对照组,差异有统计学意义(P<0.05);两组肾功能异常、肝功能异常发生率比较,差异无统计学意义(P>0.05)。结论:华蟾素胶囊联合FOLFOX方案治疗CRC患者能有效提升临床效果,降低血清肿瘤标志物和炎症水平,改善患者功能状态,减轻副毒反应。
Objective:To investigate the effect of Huachansu Capsules combined with FOLFOX regimen in the treatment of colorectal cancer(CRC)patients.Method:The clinical data of 70 patients with CRC who admitted to Zhaoqing First People's Hospital from January 2022 to February 2023 were selected for study,according to whether Huachansu Capsules was used,they were divided into the observation group(35 cases)and the control group(35 cases).The control group was treated with FOLFOX regimen,while the observation group was treated with Huachansu Capsules on the basis of the control group.The short-term efficacy,serum tumor markers,inflammatory factors,Karnofsky functional status scale(KPS)scores before and after treatment,and the occurrence of toxic and side effects during treatment were compared between two groups.Result:The total effective rate in the near future of the observation group was higher than that of the control group,the difference was statistically significant(P<0.05).Before treatment,there were no statistically significant differences in the carbohydrate antigen 242(CA242),carbohydrate antigen 125(CA125),carcinoembryonic antigen(CEA),interleukin-1β(IL-1β),interleukin-6(IL-6),tumor necrosis factor-α(TNF-α)and KPS scores between two groups(P>0.05);after treatment,the levels of CA242,CA125,CEA,IL-1β,IL-6,TNF-αof two groups decreased compared with those before treatment,and those in the observation group were lower than those in the control group,the differences were statistically significant(P<0.05);after treatment,the KPS scores of two groups increased compared with those before treatment,and that in the observation group was higher than that in the control group,the differences were statistically significant(P<0.05).The incidence of gastrointestinal reactions and leukopenia during treatment in the observation group were lower than those in the control group,and the differences were statistically significant(P<0.05);there were no statistically significant differences in the incidence of renal dysfunction and abnormal liver function between two groups(P>0.05).Conclusion:Huachansu Capsules combined with FOLFOX regimen in the treatment of CRC patients can effectively improve clinical efficacy,reduce serum tumor markers and inflammation levels,improve patient functional status,and reduce side effects.
作者
林丽湘
邵剑锋
黄金杜
LIN Lixiang;SHAO Jianfeng;HUANG Jindu(Zhaoqing First People's Hospital,Zhaoqing 526000,China;不详)
出处
《中外医学研究》
2024年第11期107-110,共4页
CHINESE AND FOREIGN MEDICAL RESEARCH
关键词
华蟾素胶囊
结直肠癌
炎症介质
Huachansu Capsules
Colorectal cancer
Inflammatory mediators
